Seasonal Allergic Rhinitis - Pipeline Insight, 2024

This “Seasonal Allergic Rhinitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seasonal Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Seasonal Allergic Rhinitis Understanding

Seasonal Allergic Rhinitis: Overview

Seasonal allergic rhinitis (SAR), also known as hay fever, is an inflammatory condition of the upper airways that occurs in response to exposure to airborne allergens (typically tree, grass, and weed pollens) in sensitized individuals. Although there is geographic variability in the seasonal emergence of allergenic pollens across the United States, tree pollens tend to emerge in the spring, grass pollens in the summer, and weed pollens in the fall. SAR is distinguished from perennial allergic rhinitis (PAR), which is triggered by continuous exposure to house dust mites, animal dander, and other allergens generally found in an individual’s indoor environment. Patients may have either SAR or PAR or both (i.e., PAR with seasonal exacerbations). Regardless of the inciting allergen(s), the four defining symptoms of allergic rhinitis are nasal discharge (rhinorrhea), nasal itching, sneezing, and/or nasal congestion. Many patients also experience symptoms of allergic conjunctivitis, such as itchy and watery eyes. Treatment effectiveness is assessed by improvement of these symptoms and improved quality of life. In children, additional symptoms of rhinitis include the allergic salute (rubbing the hand against the nose in response to itching and rhinorrhea), allergic shiner (bruised appearance of the skin under one or both eyes), and allergic crease (a wrinkle across the bridge of the nose caused by repeated allergic salute).

Seasonal Allergic Rhinitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Seasonal Allergic Rhinitis pipeline landscape is provided which includes the disease overview and Seasonal Allergic Rhinitis treatment guidelines. The assessment part of the report embraces, in depth Seasonal Allergic Rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Seasonal Allergic Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Seasonal Allergic Rhinitis.
• In the coming years, the Seasonal Allergic Rhinitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Seasonal Allergic Rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Seasonal Allergic Rhinitis treatment market. Several potential therapies for Seasonal Allergic Rhinitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Seasonal Allergic Rhinitis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Seasonal Allergic Rhinitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Seasonal Allergic Rhinitis Emerging Drugs Chapters

This segment of the Seasonal Allergic Rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Seasonal Allergic Rhinitis Emerging Drugs

IRL 201104: Revolo BiotherapeuticsIRL 201104 is a first-in-class peptide derived from a natural immune-regulatory protein, mTB Chaperonin 60.1 that is involved in resetting the immune system. Revolo Bio is advancing ‘1104 through two Phase 2 trials: one in patients with eosinophilic esophagitis (EoE) and one in patients with allergen sensitivity, while exploring its potential for other allergic diseases. Currently, it is in Phase II stage of clinical trial evaluation to treat Seasonal allergic rhinitis.

ILT-101: ILTOO PharmaILT-101 (Aldesleukin/Proleukin) is a low dose human recombinant interleukin 2 (rhIL2), for the treatment of allergic rhinoconjunctivitic, metastatic renal cell carcinoma and metastatic melanoma. Currently, it is in Phase II stage of clinical trial evaluation to treat Seasonal allergic rhinitis.

Seasonal Allergic Rhinitis: Therapeutic Assessment

This segment of the report provides insights about the different Seasonal Allergic Rhinitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Seasonal Allergic Rhinitis

There are approx. 5+ key companies which are developing the therapies for Seasonal Allergic Rhinitis. The companies which have their Seasonal Allergic Rhinitis drug candidates in the most advanced stage, i.e. phase II include, Revolo Biotherapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Seasonal Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Seasonal Allergic Rhinitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Seasonal Allergic Rhinitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Seasonal Allergic Rhinitis drugs.

Seasonal Allergic Rhinitis Report Insights

• Seasonal Allergic Rhinitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Seasonal Allergic Rhinitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Seasonal Allergic Rhinitis drugs?
• How many Seasonal Allergic Rhinitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Seasonal Allergic Rhinitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Seasonal Allergic Rhinitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Seasonal Allergic Rhinitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Revolo Biotherapeutics
• ILTOO Pharma
• Anhui Palo Alto Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals
• Funpep
• Allergy Therapeutics

Key Products

• IRL 201104
• ILT-101
• PA9159
• REGN5713-5714-5715
• FPP004
• Grass MATA MPL

This product will be delivered within 2 business days.